Skip to main content
An official website of the United States government
Grant Details

Grant Number: 5R01CA248288-04 Interpret this number
Primary Investigator: Goode, Ellen
Organization: Mayo Clinic Rochester
Project Title: Relating Molecular Subgroups of Endometriosis-Associated Ovarian Cancers to Survival and Risk
Fiscal Year: 2024


Abstract

PROJECT SUMMARY/ABSTRACT Ovarian cancer (OC) is the eleventh most common cancer and fifth deadliest among U.S. women. The low incidence, high fatality and molecularly broad range of tumor histotypes make OC challenging to study and to treat. Consequently, survival rates have scarcely changed over the past 35 years, largely because precision therapy lags behind most other cancers. Endometrioid (ENOC) and clear cell (CCOC) account for ~25% of all invasive OC. They are a heterogeneous and understudied group of tumors that are closely associated with endometriosis, but show few similarities to the more common high grade serous OC. ENOC or CCOC have variable or poor response to standard platinum-based chemotherapy. CCOC, in particular, is more likely to be platinum resistant at early stage and resistant to second line chemotherapy at advanced stage, resulting in worse survival than HGSOC. We hypothesize that molecular tumor subtypes exist for ENOC and CCOC that reflect differences in biological processes and risk factors and that might inform new treatment strategies. Our preliminary results using genomics analyses of 185 ENOC and 115 CCOC supports this hypothesis by showing that associations with survival and risk factors such as smoking and body mass index differ according to the tumor’s molecular profile, with some subgroups showing rapidly fatal outcome. In the current proposal, we intend to delve deeper into the genomic profile of ~1,100 ENOC and CCOC tumors to identify key molecular features of the tumor subtypes. Our approach uses a consortium effort that combines existing data from well-conducted epidemiologic studies of risk factors with corresponding clinical information among investigators with a strong history of collaboration. We will first characterize molecular subtypes, separately for ENOC and CCOC, by integrating sequencing and array data from gene expression, mutations and methylated regions from a training set (483 ENOC, 292 CCOC) using statistical clustering. Next, we will assess replication of the molecular subtypes in an independent test set (207 ENOC, 125 CCOC). To assess subtype-specific associations in the total sample (689 ENOC, 417 CCOC), we will relate molecular subtypes of ENOC and CCOC separately to risk factors and to survival. Impact: Less common OC such as ENOC or CCOC are often overshadowed by investigations of more common cancers, yet our data show that ENOC and CCOC can also be rapidly fatal in certain patient subsets or show more favorable outcome in others, directly impacting patients’ lives. Finding patterns with other cancers by using integrated analysis of ENOC and CCOC subtypes has high potential to inform new avenues for targeted therapy and to enhance understanding of ENOC and CCOC cancer biology. Future replication of our findings using an independent 1,400 ENOC/CCOC tumors from our unique consortia resources can lead to needed gains in biological, epidemiologic and therapeutic insights for these patients.



Publications

Concurrent RB1 Loss and BRCA Deficiency Predicts Enhanced Immunologic Response and Long-term Survival in Tubo-ovarian High-grade Serous Carcinoma.
Authors: Saner F.A.M. , Takahashi K. , Budden T. , Pandey A. , Ariyaratne D. , Zwimpfer T.A. , Meagher N.S. , Fereday S. , Twomey L. , Pishas K.I. , et al. .
Source: Clinical Cancer Research : An Official Journal Of The American Association For Cancer Research, 2024-08-15 00:00:00.0; 30(16), p. 3481-3498.
PMID: 38837893
Related Citations

Integrative multi-omics analyses to identify the genetic and functional mechanisms underlying ovarian cancer risk regions.
Authors: Dareng E.O. , Coetzee S.G. , Tyrer J.P. , Peng P.C. , Rosenow W. , Chen S. , Davis B.D. , Dezem F.S. , Seo J.H. , Nameki R. , et al. .
Source: American Journal Of Human Genetics, 2024-05-07 00:00:00.0; , .
EPub date: 2024-05-07 00:00:00.0.
PMID: 38723632
Related Citations

Risk Factors for Ovarian Cancer by BRCA Status: A Collaborative Case-Only Analysis.
Authors: Gersekowski K. , Na R. , Alsop K. , Delahunty R. , Goode E.L. , Cunningham J.M. , Winham S.J. , Pharoah P.D.P. , Song H. , Webb P.M. .
Source: Cancer Epidemiology, Biomarkers & Prevention : A Publication Of The American Association For Cancer Research, Cosponsored By The American Society Of Preventive Oncology, 2024-04-03 00:00:00.0; 33(4), p. 586-592.
PMID: 38300121
Related Citations

Exome sequencing identifies HELB as a novel susceptibility gene for non-mucinous, non-high-grade-serous epithelial ovarian cancer.
Authors: Dicks E.M. , Tyrer J.P. , Ezquina S. , Jones M. , Baierl J. , Peng P.C. , Diaz M. , Goode E. , Winham S.J. , Dörk T. , et al. .
Source: Medrxiv : The Preprint Server For Health Sciences, 2024-04-03 00:00:00.0; , .
EPub date: 2024-04-03 00:00:00.0.
PMID: 38633804
Related Citations

Proteogenomic analysis of enriched HGSOC tumor epithelium identifies prognostic signatures and therapeutic vulnerabilities.
Authors: Bateman N.W. , Abulez T. , Soltis A.R. , McPherson A. , Choi S. , Garsed D.W. , Pandey A. , Tian C. , Hood B.L. , Conrads K.A. , et al. .
Source: Npj Precision Oncology, 2024-03-13 00:00:00.0; 8(1), p. 68.
EPub date: 2024-03-13 00:00:00.0.
PMID: 38480868
Related Citations

Genome-wide association analyses of ovarian cancer patients undergoing primary debulking surgery identify candidate genes for residual disease.
Authors: Ramachandran D. , Tyrer J.P. , Kommoss S. , DeFazio A. , Riggan M.J. , AOCS Group , Webb P.M. , Fasching P.A. , Lambrechts D. , García M.J. , et al. .
Source: Npj Genomic Medicine, 2024-03-05 00:00:00.0; 9(1), p. 19.
EPub date: 2024-03-05 00:00:00.0.
PMID: 38443389
Related Citations

Large-scale genome-wide association study of 398,238 women unveils seven novel loci associated with high-grade serous epithelial ovarian cancer risk.
Authors: Barnes D.R. , Tyrer J.P. , Dennis J. , Leslie G. , Bolla M.K. , Lush M. , Aeilts A.M. , Aittomäki K. , Andrieu N. , Andrulis I.L. , et al. .
Source: Medrxiv : The Preprint Server For Health Sciences, 2024-03-04 00:00:00.0; , .
EPub date: 2024-03-04 00:00:00.0.
PMID: 38496424
Related Citations

Concurrent RB1 loss and BRCA-deficiency predicts enhanced immunological response and long-term survival in tubo-ovarian high-grade serous carcinoma.
Authors: Saner F.A.M. , Takahashi K. , Budden T. , Pandey A. , Ariyaratne D. , Zwimpfer T.A. , Meagher N.S. , Fereday S. , Twomey L. , Pishas K.I. , et al. .
Source: Medrxiv : The Preprint Server For Health Sciences, 2023-11-10 00:00:00.0; , .
EPub date: 2023-11-10 00:00:00.0.
PMID: 37986741
Related Citations

Batch-effect correction with sample remeasurement in highly confounded case-control studies.
Authors: Ye H. , Zhang X. , Wang C. , Goode E.L. , Chen J. .
Source: Nature Computational Science, 2023 Aug; 3(8), p. 709-719.
EPub date: 2023-08-23 00:00:00.0.
PMID: 38177326
Related Citations

The prognostic effect of immune cell infiltration depends on molecular subtype in Endometrioid Ovarian Carcinomas.
Authors: Heinze K. , Cairns E.S. , Thornton S. , Harris B. , Milne K. , Grube M. , Meyer C. , Karnezis A.N. , Fereday S. , Garsed D.W. , et al. .
Source: Clinical Cancer Research : An Official Journal Of The American Association For Cancer Research, 2023-06-20 00:00:00.0; , .
EPub date: 2023-06-20 00:00:00.0.
PMID: 37339172
Related Citations

Lifetime ovulatory years and risk of epithelial ovarian cancer: a multinational pooled analysis.
Authors: Fu Z. , Brooks M.M. , Irvin S. , Jordan S. , Aben K.K.H. , Anton-Culver H. , Bandera E.V. , Beckmann M.W. , Berchuck A. , Brooks-Wilson A. , et al. .
Source: Journal Of The National Cancer Institute, 2023-05-08 00:00:00.0; 115(5), p. 539-551.
PMID: 36688720
Related Citations

Clinical parameters affecting survival outcomes in patients with low-grade serous ovarian carcinoma: an international multicentre analysis.
Authors: May T. , Bernardini M. , Lheureux S. , Aben K.K.H. , Bandera E.V. , Beckmann M.W. , Benitez J. , Berchuck A. , Bjørge L. , Carney M.E. , et al. .
Source: Canadian Journal Of Surgery. Journal Canadien De Chirurgie, 2023 May-Jun; 66(3), p. E310-E320.
EPub date: 2023-06-27 00:00:00.0.
PMID: 37369443
Related Citations

Methylation Signature Implicated in Immuno-Suppressive Activities in Tubo-Ovarian High-Grade Serous Carcinoma.
Authors: Wang C. , Block M.S. , Cunningham J.M. , Sherman M.E. , McCauley B.M. , Armasu S.M. , Vierkant R.A. , Traficante N. , Australian Ovarian Cancer Study Group , Talhouk A. , et al. .
Source: Cancer Epidemiology, Biomarkers & Prevention : A Publication Of The American Association For Cancer Research, Cosponsored By The American Society Of Preventive Oncology, 2023-04-03 00:00:00.0; 32(4), p. 542-549.
PMID: 36790339
Related Citations

p53 and ovarian carcinoma survival: an Ovarian Tumor Tissue Analysis consortium study.
Authors: Köbel M. , Kang E.Y. , Weir A. , Rambau P.F. , Lee C.H. , Nelson G.S. , Ghatage P. , Meagher N.S. , Riggan M.J. , Alsop J. , et al. .
Source: The Journal Of Pathology. Clinical Research, 2023-03-22 00:00:00.0; , .
EPub date: 2023-03-22 00:00:00.0.
PMID: 36948887
Related Citations

Multiplex Immunofluorescence Image Quality Checking Using DAPI Channel-referenced Evaluation.
Authors: Jiang J. , Moore R. , Jordan C.E. , Guo R. , Maus R.L. , Liu H. , Goode E. , Markovic S.N. , Wang C. .
Source: The Journal Of Histochemistry And Cytochemistry : Official Journal Of The Histochemistry Society, 2023 Mar; 71(3), p. 121-130.
EPub date: 2023-03-24 00:00:00.0.
PMID: 36960831
Related Citations

Increased FOXJ1 protein expression is associated with improved overall survival in high-grade serous ovarian carcinoma: an Ovarian Tumor Tissue Analysis Consortium Study.
Authors: Weir A. , Kang E.Y. , Meagher N.S. , Nelson G.S. , Ghatage P. , Lee C.H. , Riggan M.J. , Gentry-Maharaj A. , Ryan A. , Singh N. , et al. .
Source: British Journal Of Cancer, 2023 Jan; 128(1), p. 137-147.
EPub date: 2022-11-02 00:00:00.0.
PMID: 36323878
Related Citations

Lifestyle and personal factors associated with having macroscopic residual disease after ovarian cancer primary cytoreductive surgery.
Authors: Phung M.T. , Webb P.M. , DeFazio A. , Fereday S. , Lee A.W. , Bowtell D.D.L. , Fasching P.A. , Goode E.L. , Goodman M.T. , Karlan B.Y. , et al. .
Source: Gynecologic Oncology, 2023 Jan; 168, p. 68-75.
EPub date: 2022-11-17 00:00:00.0.
PMID: 36401943
Related Citations

CCNE1 and survival of patients with tubo-ovarian high-grade serous carcinoma: An Ovarian Tumor Tissue Analysis consortium study.
Authors: Kang E.Y. , Weir A. , Meagher N.S. , Farrington K. , Nelson G.S. , Ghatage P. , Lee C.H. , Riggan M.J. , Bolithon A. , Popovic G. , et al. .
Source: Cancer, 2022-12-26 00:00:00.0; , .
EPub date: 2022-12-26 00:00:00.0.
PMID: 36572991
Related Citations

The genomic and immune landscape of long-term survivors of high-grade serous ovarian cancer.
Authors: Garsed D.W. , Pandey A. , Fereday S. , Kennedy C.J. , Takahashi K. , Alsop K. , Hamilton P.T. , Hendley J. , Chiew Y.E. , Traficante N. , et al. .
Source: Nature Genetics, 2022 Dec; 54(12), p. 1853-1864.
EPub date: 2022-12-01 00:00:00.0.
PMID: 36456881
Related Citations

Into the future: A pilot study combining imaging with molecular profiling to predict resectability in ovarian cancer.
Authors: Kumar A. , Wang C. , Sheedy S.P. , McCauley B.M. , Winham S.J. , Ramus S.J. , Anglesio M.S. , Kim B. , Torres D. , Keeney G.L. , et al. .
Source: Gynecologic Oncology, 2022 09; 166(3), p. 508-514.
EPub date: 2022-08-02 00:00:00.0.
PMID: 35931468
Related Citations

The proteome of clear cell ovarian carcinoma.
Authors: Ji J.X. , Cochrane D. , Negri G.L. , Colborne S. , Spencer Miko S.E. , Hoang L.N. , Farnell D. , Tessier-Cloutier B. , Huvila J. , Thompson E. , et al. .
Source: The Journal Of Pathology, 2022-08-28 00:00:00.0; , .
EPub date: 2022-08-28 00:00:00.0.
PMID: 36031730
Related Citations

Molecular subclasses of clear cell ovarian carcinoma and their impact on disease behavior and outcomes.
Authors: Bolton K.L. , Chen D. , Corona de la Fuente R.I. , Fu Z. , Murali R. , Köbel M. , Tazi Y. , Cunningham J.M. , Chan I.C.C. , Wiley B.J. , et al. .
Source: Clinical Cancer Research : An Official Journal Of The American Association For Cancer Research, 2022-07-11 00:00:00.0; , .
EPub date: 2022-07-11 00:00:00.0.
PMID: 35816189
Related Citations

Germline BRCA variants, lifestyle and ovarian cancer survival.
Authors: Gersekowski K. , Delahunty R. , Alsop K. , Goode E.L. , Cunningham J.M. , Winham S.J. , Pharoah P. , Song H. , Jordan S. , Fereday S. , et al. .
Source: Gynecologic Oncology, 2022 06; 165(3), p. 437-445.
EPub date: 2022-04-07 00:00:00.0.
PMID: 35400525
Related Citations

Correction: Polygenic risk modeling for prediction of epithelial ovarian cancer risk.
Authors: Dareng E.O. , Tyrer J.P. , Barnes D.R. , Jones M.R. , Yang X. , Aben K.K.H. , Adank M.A. , Agata S. , Andrulis I.L. , Anton-Culver H. , et al. .
Source: European Journal Of Human Genetics : Ejhg, 2022 May; 30(5), p. 630-631.
PMID: 35314806
Related Citations

CA-125 Levels Are Predictive of Survival in Low-Grade Serous Ovarian Cancer-A Multicenter Analysis.
Authors: Wohlmuth C. , Djedovic V. , Kjaer S.K. , Jensen A. , Glasspool R. , Roxburgh P. , DeFazio A. , Johnatty S.E. , Webb P.M. , Modugno F. , et al. .
Source: Cancers, 2022-04-13 00:00:00.0; 14(8), .
EPub date: 2022-04-13 00:00:00.0.
PMID: 35454861
Related Citations

Polygenic risk modeling for prediction of epithelial ovarian cancer risk.
Authors: Dareng E.O. , Tyrer J.P. , Barnes D.R. , Jones M.R. , Yang X. , Aben K.K.H. , Adank M.A. , Agata S. , Andrulis I.L. , Anton-Culver H. , et al. .
Source: European Journal Of Human Genetics : Ejhg, 2022 03; 30(3), p. 349-362.
EPub date: 2022-01-14 00:00:00.0.
PMID: 35027648
Related Citations

High Prediagnosis Inflammation-Related Risk Score Associated with Decreased Ovarian Cancer Survival.
Authors: Brieger K.K. , Phung M.T. , Mukherjee B. , Bakulski K.M. , Anton-Culver H. , Bandera E.V. , Bowtell D.D.L. , Cramer D.W. , DeFazio A. , Doherty J.A. , et al. .
Source: Cancer Epidemiology, Biomarkers & Prevention : A Publication Of The American Association For Cancer Research, Cosponsored By The American Society Of Preventive Oncology, 2022 02; 31(2), p. 443-452.
EPub date: 2021-11-17 00:00:00.0.
PMID: 34789471
Related Citations

Computational tumor stroma reaction evaluation led to novel prognosis-associated fibrosis and molecular signature discoveries in high-grade serous ovarian carcinoma.
Authors: Jiang J. , Tekin B. , Yuan L. , Armasu S. , Winham S.J. , Goode E.L. , Liu H. , Huang Y. , Guo R. , Wang C. .
Source: Frontiers In Medicine, 2022; 9, p. 994467.
EPub date: 2022-09-07 00:00:00.0.
PMID: 36160147
Related Citations

Validated biomarker assays confirm that ARID1A loss is confounded with MMR deficiency, CD8+ TIL infiltration, and provides no independent prognostic value in endometriosis-associated ovarian carcinomas.
Authors: Heinze K. , Nazeran T.M. , Lee S. , Krämer P. , Cairns E.S. , Chiu D.S. , Leung S.C. , Kang E.Y. , Meagher N.S. , Kennedy C.J. , et al. .
Source: The Journal Of Pathology, 2021-12-13 00:00:00.0; , .
EPub date: 2021-12-13 00:00:00.0.
PMID: 34897700
Related Citations

MCM3 is a novel proliferation marker associated with longer survival for patients with tubo-ovarian high-grade serous carcinoma.
Authors: Kang E.Y. , Millstein J. , Popovic G. , Meagher N.S. , Bolithon A. , Talhouk A. , Chiu D.S. , Anglesio M.S. , Leung B. , Tang K. , et al. .
Source: Virchows Archiv : An International Journal Of Pathology, 2021-11-15 00:00:00.0; , .
EPub date: 2021-11-15 00:00:00.0.
PMID: 34782936
Related Citations

DNA Methylation Profiles of Ovarian Clear Cell Carcinoma.
Authors: Cunningham J.M. , Winham S.J. , Wang C. , Weigelt B. , Fu Z. , Armasu S.M. , McCauley B.M. , Brand A.H. , Chiew Y.E. , Elishaev E. , et al. .
Source: Cancer Epidemiology, Biomarkers & Prevention : A Publication Of The American Association For Cancer Research, Cosponsored By The American Society Of Preventive Oncology, 2021-10-25 00:00:00.0; , .
EPub date: 2021-10-25 00:00:00.0.
PMID: 34697060
Related Citations

Pleiotropy-guided transcriptome imputation from normal and tumor tissues identifies candidate susceptibility genes for breast and ovarian cancer.
Authors: Kar S.P. , Considine D.P.C. , Tyrer J.P. , Plummer J.T. , Chen S. , Dezem F.S. , Barbeira A.N. , Rajagopal P.S. , Rosenow W.T. , Moreno F. , et al. .
Source: Hgg Advances, 2021-07-08 00:00:00.0; 2(3), .
EPub date: 2021-06-16 00:00:00.0.
PMID: 34317694
Related Citations

Identification of a Locus Near ULK1 Associated With Progression-Free Survival in Ovarian Cancer.
Authors: Quinn M.C.J. , McCue K. , Shi W. , Johnatty S.E. , Beesley J. , Civitarese A. , O'Mara T.A. , Glubb D.M. , Tyrer J.P. , Armasu S.M. , et al. .
Source: Cancer Epidemiology, Biomarkers & Prevention : A Publication Of The American Association For Cancer Research, Cosponsored By The American Society Of Preventive Oncology, 2021-06-23 00:00:00.0; , .
EPub date: 2021-06-23 00:00:00.0.
PMID: 34162658
Related Citations

Frequent POLE-driven hypermutation in ovarian endometrioid cancer revealed by mutational signatures in RNA sequencing.
Authors: Davila J.I. , Chanana P. , Sarangi V. , Fogarty Z.C. , Weroha S.J. , Guo R. , Goode E.L. , Huang Y. , Wang C. .
Source: Bmc Medical Genomics, 2021-06-22 00:00:00.0; 14(1), p. 165.
EPub date: 2021-06-22 00:00:00.0.
PMID: 34158040
Related Citations

Gene-based mediation analysis in epigenetic studies.
Authors: Fang R. , Yang H. , Gao Y. , Cao H. , Goode E.L. , Cui Y. .
Source: Briefings In Bioinformatics, 2021-05-20 00:00:00.0; 22(3), .
PMID: 32608480
Related Citations

Population-based targeted sequencing of 54 candidate genes identifies PALB2 as a susceptibility gene for high-grade serous ovarian cancer.
Authors: Song H. , Dicks E.M. , Tyrer J. , Intermaggio M. , Chenevix-Trench G. , Bowtell D.D. , Traficante N. , Group A. , Brenton J. , Goranova T. , et al. .
Source: Journal Of Medical Genetics, 2021 May; 58(5), p. 305-313.
EPub date: 2020-06-16 00:00:00.0.
PMID: 32546565
Related Citations

Expanding Our Understanding of Ovarian Cancer Risk: The Role of Incomplete Pregnancies.
Authors: Lee A.W. , Rosenzweig S. , Wiensch A. , Australian Ovarian Cancer Study Group , Ramus S.J. , Menon U. , Gentry-Maharaj A. , Ziogas A. , Anton-Culver H. , Whittemore A.S. , et al. .
Source: Journal Of The National Cancer Institute, 2021-03-01 00:00:00.0; 113(3), p. 301-308.
PMID: 32766851
Related Citations

Circulating CD14+ HLA-DRlo/- monocytic cells as a biomarker for epithelial ovarian cancer progression.
Authors: Stenzel A.E. , Abrams S.I. , Joseph J.M. , Goode E.L. , Tario J.D. , Wallace P.K. , Kaur D. , Adamson A.K. , Buas M.F. , Lugade A.A. , et al. .
Source: American Journal Of Reproductive Immunology (new York, N.y. : 1989), 2021 03; 85(3), p. e13343.
EPub date: 2020-09-21 00:00:00.0.
PMID: 32905653
Related Citations

Generating real-world evidence from unstructured clinical notes to examine clinical utility of genetic tests: use case in BRCAness.
Authors: Zhao Y. , Weroha S.J. , Goode E.L. , Liu H. , Wang C. .
Source: Bmc Medical Informatics And Decision Making, 2021-01-06 00:00:00.0; 21(1), p. 3.
EPub date: 2021-01-06 00:00:00.0.
PMID: 33407429
Related Citations



Back to Top